Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dhaval Desai

Interventional Cardiology Corona, CA Medical Doctor

NPI 1164798153 CMS profile 710281

2250 S Main St Ste 201, Corona, CA 92882

Open in the dashboard

General payments

$118,097

187 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dhaval Desai of Corona, CA is reported in the CMS Open Payments database as having received $118,097 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,527 18
2024 General $229 5
2023 General $67,315 10
2022 General $1,125 54
2021 General $269 15
2020 General $1,364 26
2019 General $46,268 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dhaval Desai
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Dhaval Desai were reported at $1,527. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Dhaval Desai Interventional Cardiology median Middle half National median
2019 $46,268 $1,097 $329–$3,048 $163
2020 $1,364 $473 $161–$1,480 $114
2021 $269 $677 $233–$1,827 $132
2022 $1,125 $978 $333–$2,724 $149
2023 $67,315 $1,136 $382–$2,986 $160
2024 $229 $1,181 $395–$3,326 $164
2025 $1,527 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amryt Pharma Holdings Ltd $67,086 5 payments
  2. Boston Scientific Corporation $25,890 21 payments
  3. Medtronic Vascular, Inc. $18,899 13 payments
  4. Edwards Lifesciences Corporation $2,836 36 payments
  5. Abbott Laboratories $436 8 payments
  6. Medtronic, Inc. $408 10 payments
  7. AstraZeneca Pharmaceuticals LP $304 13 payments
  8. Chiesi USA, Inc. $221 8 payments
  9. W. L. Gore & Associates, Inc. $215 2 payments
  10. Shockwave Medical, Inc $194 7 payments
  11. Other $1,608 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $67,086 5 payments
  2. Grant $43,000 2 payments
  3. Food and Beverage $7,251 175 payments
  4. Travel and Lodging $612 3 payments
  5. Education $147 2 payments
Products named General payments · program years 2019–2025
  1. MYALEPT $67,086 5 payments
  2. GENERAL STRUCTURAL HEART $25,000 1 payment
  3. CoreValve Evolut $18,899 13 payments
  4. SAPIEN 3 Ultra RESILIA $1,397 14 payments
  5. Edwards SAPIEN 3 Transcatheter Heart Valve $1,070 12 payments
  6. Optis Coronary Imaging System $307 2 payments
  7. Synergy $281 3 payments
  8. GENERAL STENTS $271 6 payments
  9. BRILINTA $224 8 payments
  10. KENGREAL $221 8 payments
  11. Other $3,245 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

42

Median for Interventional Cardiology: 2,236

Drug cost

$660

Median for Interventional Cardiology: $380,412

Branded share of claims

64.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 27 $507
Furosemide Generic 15 $153

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record